Evidence map›Paper›PMID 42629416›Full record

ReviewNature immunology2026

Collaborative functionality between three types of inflammation in idiopathic pulmonary fibrosis.

Thomas Fabre, Thomas A Wynn, Kevin M Hart

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Thomas FabrePfizer, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-4394-4533
Thomas A WynnPfizer, Cambridge, MA, USA.
Kevin M HartPfizer, Cambridge, MA, USA. Kevin.Hart@pfizer.com.ORCID http://orcid.org/0000-0001-5406-5473

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and chronic interstitial lung disease with significant unmet need, and only a few therapeutic options slow decline rather than improve function. An expanding fibrotic niche is one hallmark of this disease, comprising a multicellular environment characterized by epithelial dysfunction and death, infiltration of peripheral immune cells, differentiation of fibroblasts and immune cells, extracellular matrix turnover and deposition of fibrillar collagen. Inflammation is a master regulator spanning all aspects of this fibrotic niche through cellular players and signaling mediators that can be split into three primary types. In many immune responses, the inflammatory milieu is dominated by one type of inflammation at a time, but recent findings suggest there might be more spatial and kinetic overlap present in fibrotic diseases, including IPF, than previously appreciated. In this Review, we summarize some of the key cellular players and soluble mediators involved in IPF progression and how distinct types of inflammation jointly regulate disease progression in concert rather than focus on individual cytokines or immune cells.

Indexed as

Idiopathic Pulmonary FibrosisInflammationAnimalsCytokinesDisease ProgressionFibroblastsHumansInflammation MediatorsSignal TransductionCytokinesInflammation Mediators

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.